Toggle Main Menu Toggle Search

Open Access padlockePrints

Preliminary assessment of midazolam, fentanyl and fluanisone combination for the sedation of rhesus macaques (Macaca mulatta)

Lookup NU author(s): Henri Bertrand, Emeritus Professor Paul FlecknellORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2016, © The Author(s) 2016. This study was undertaken to assess the suitability of fentanyl/fluanisone (‘Hypnorm’, VetaPharma; 0.315 mg/mL of fentanyl citrate and 10 mg/mL of fluanisone) alone or combined with midazolam in rhesus macaques. Fifteen rhesus macaques requiring sedation for veterinary procedures received an intramuscular (IM) dose range of Hypnorm from 0.01 mL/kg to 0.3 mL/kg either alone or combined with 0.5 mg/kg of midazolam. To reverse the sedation, flumazenil in combination with either naloxone, buprenorphine or butorphanol was administered intravenously (IV) or IM. Rhesus macaques were successfully sedated with 0.1 mL/kg of Hypnorm and 0.5 mg/kg of midazolam, and sedation was partially reversed by the administration of flumazenil and either naloxone or buprenorphine. However the primates remained slightly sedated and were only released into their home cage several hours post recovery. Butorphanol failed to induce recovery and caused marked respiratory depression. The neuroleptanalgesic combination, Hypnorm and midazolam, effectively immobilized rhesus macaques and was reversible with a combination of flumazenil and either naloxone or buprenorphine.


Publication metadata

Author(s): Bertrand HGMJ, Sandersen CF, Flecknell PA

Publication type: Article

Publication status: Published

Journal: Laboratory Animals

Year: 2017

Volume: 51

Issue: 4

Pages: 405-411

Print publication date: 01/08/2017

Online publication date: 08/12/2016

Acceptance date: 02/04/2016

ISSN (print): 0023-6772

ISSN (electronic): 1758-1117

Publisher: SAGE Publications Ltd

URL: https://doi.org/10.1177/0023677216675385

DOI: 10.1177/0023677216675385


Altmetrics

Altmetrics provided by Altmetric


Share